Landscape of driver gene events, biomarkers, and druggable targets identified by whole-genome sequencing of glioblastomas.

ABSTRACT:

Background

The survival of glioblastoma patients is poor. Median survival after diagnosis is 15 months, despite treatment involving surgical resection, radiotherapy, and/or temozolomide chemotherapy. Identification of novel targets and stratification strategies of glioblastoma patients to improve patient survival is urgently needed. Whole-genome sequencing (WGS) is the most comprehensive means to identify such DNA-level targets. We report a unique set of WGS samples along with comprehensive analyses of the glioblastoma genome and potential clinical impact of WGS.

Methods

Our cohort consisted of 42 glioblastoma tumor tissue and matched whole-blood samples, which were whole-genome sequenced as part of the CPCT-02 study. Somatic single-nucleotide variants, small insertions/dele

SUBMITTER: van de Geer WS 

PROVIDER: S-EPMC8760899 | biostudies-literature | 2022 Jan-Dec

REPOSITORIES: biostudies-literature